UroGen Pharma (URGN) said Tuesday the US Food and Drug Administration accepted the new drug application for UGN-102 as an intravesical solution to treat low-grade intermediate-risk non-muscle invasive bladder cancer.
The FDA has set a Prescription Drug User Fee Act target action date of June 13, 2025, the company said.
The application is backed by data from three clinical studies that show durability of response and a favorable safety profile, according to UroGen.
Price: 12.10, Change: -0.16, Percent Change: -1.31
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.